Top 50 Ai For Drug Discovery in Asia

The startup utilizes artificial intelligence and big data analytics to enhance drug discovery and development for cancers and rare diseases. Their in-house research facility focuses on accelerating the identification of effective treatments, addressing the lengthy and costly process of bringing new drugs to market.

Villanelle Life develops AI-driven platforms for drug discovery, early disease screening, and diagnostic support. Their technology aims to accelerate the identification of potential drug candidates and improve disease detection and diagnosis.

Zhiyao Technology utilizes artificial intelligence and machine learning techniques, including molecular modeling and deep learning, to enhance the efficiency and success rate of drug discovery for small molecules and proteins. The company provides software and technical services to pharmaceutical firms and research institutions, addressing the challenges of high costs and low success rates in new drug development.

CarbonSilicon AI provides an AI-driven platform for drug discovery that integrates deep learning, knowledge graphs, and 3D modeling to enhance target identification and safety predictions. This technology streamlines the drug development process, reducing time and costs associated with traditional research methods.

Medvolt is an AI platform that utilizes generative AI and physics-based simulations to enhance early-stage drug discovery and repurposing, significantly reducing pre-clinical discovery time by threefold and costs by fifteenfold. The platform's modular design allows pharmaceutical and biotech companies to efficiently generate novel compounds and therapeutic targets while minimizing the risk of failure in drug development.

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

Artivila Therapeutics utilizes an AI-powered drug discovery engine that integrates computational chemistry and synthetic biology to identify new drug targets in oncology, autoimmune diseases, and neurodegenerative disorders. The platform significantly reduces research and development costs and timelines while increasing the probability of successful drug outcomes for unmet medical needs.

BJ Biopharma utilizes proprietary AI algorithms to design and test drug candidates, streamlining the drug development process from molecule design to in vitro and in vivo testing. This approach addresses the inefficiencies in traditional drug discovery, significantly accelerating the time to market for new therapeutics.

SK Therapeutics is an AI-driven platform that accelerates drug development by utilizing machine learning algorithms to identify potential drug candidates and optimize their efficacy. This approach addresses the lengthy and costly traditional drug discovery process, significantly reducing time-to-market for new therapeutics.

TandemAI provides a physics-based and AI-driven platform that integrates computational analyses with wet lab experimentation to enhance drug discovery workflows. By offering a collaborative workspace and advanced algorithms, TandemAI enables research teams to accelerate the development of new therapeutics more efficiently than traditional methods.

Cimplrx utilizes its Explainable Artificial Intelligence platform, CEEK-CURE, to streamline drug discovery by generating predictive models for compound design and target identification. This technology addresses the inefficiencies in traditional drug development processes by automating data analysis and visualization, enabling faster and more informed decision-making in the identification of new drug candidates.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

Scitech Pharma utilizes its proprietary SigmaHIT® program to design and develop small molecule drugs targeting oncology, autoimmune diseases, and central nervous system disorders. The company accelerates drug development by rapidly synthesizing and optimizing candidates through AI-driven methodologies, enhancing the efficiency of bringing new therapies to market.

ZipBio uses generative AI to design compact, multispecific protein therapeutics called Zip® drugs, enabling the creation of novel biologics that are difficult to produce with traditional methods. These smart proteins target unmet medical needs across various disease areas, and the company monetizes its pipeline through licensing, partnerships, and eventual product sales. The platform aims to accelerate drug development by compressing biological complexity into engineered therapeutic candidates.

Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.

Quris offers a Bio-AI Clinical Prediction Platform that utilizes machine learning trained on miniaturized Patients-on-a-Chip to predict the safety of drug candidates in humans. This approach aims to reduce the high failure rate of clinical trials, which currently sees 89% of drugs not making it to market, thereby lowering development costs.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

Xilingyuan Pharmaceutical utilizes advanced computational modeling and data analytics to streamline the drug development process, significantly reducing time-to-market for new therapeutics. The company addresses the inefficiencies and high costs associated with traditional drug discovery methods, enabling faster and more cost-effective solutions for pharmaceutical innovation.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

The startup utilizes artificial intelligence and biochip technology to simulate patient drug reactions, enabling precise predictions of individual responses to medications. This approach provides tailored medical solutions, enhancing patient outcomes through data-driven insights into optimal drug therapies.

This startup provides a medical image data platform specializing in radiology and pathology. It selects, annotates, and standardizes medical image data from facilities, then sells this anonymized information to pharmaceutical companies for AI research and development. The company also offers contract development, consulting, and marketing services using these datasets.

Phil Rivers Technology provides an AI-driven research and development platform for the pharmaceutical industry, utilizing machine learning algorithms to optimize drug discovery processes. The solution reduces the time and cost associated with bringing new drugs to market by enhancing data analysis and predictive modeling capabilities.

MolNavi utilizes molecular navigation technologies to enhance drug discovery and materials science processes. The company focuses on improving the efficiency and accuracy of identifying viable compounds, addressing the lengthy and costly nature of traditional drug development.

The startup develops pharmaceutical chemical technology that utilizes protein structure identification and genomics to identify new drug candidates. This approach enhances the efficiency of drug discovery, enabling the development of effective treatments for patients.

Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.

Adagene operates an AI‑driven antibody discovery platform that models the full conformational landscape of target proteins to identify high‑affinity binders. The system generates three proprietary formats—NEObody for targeting previously inaccessible epitopes, SAFEbody for tumor‑localized activation via precision masking, and POWERbody that combines masking with bispecific, ADC, or T‑cell engager configurations. The company offers these candidates as licensed assets or co‑development projects to biopharma partners seeking safer, multi‑modal oncology therapeutics.

iRegene develops pharmaceutical therapies utilizing gene editing and AI-driven omics analysis to create fast-acting, disease-reversing treatments for neurodegenerative and rare diseases. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Parkinson's disease and ischemic stroke.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

This company analyzes microbiome data using AI to provide insights into human health. Their platform helps researchers and healthcare professionals understand the role of the microbiome in disease and develop personalized interventions.

Tianhu Technology specializes in computational chemistry and AI-driven protein design, focusing on enzyme modification and drug molecule development to enhance drug efficacy and reduce manufacturing costs. By leveraging extensive protein sequence data, the company delivers tailored solutions that improve product performance and shorten R&D cycles across various biopharmaceutical applications.

This company likely develops artificial intelligence solutions tailored for the healthcare sector. Their focus is on leveraging machine learning for applications such as diagnostics, patient management, or operational efficiency within medical systems. The core value proposition centers on integrating advanced AI technology to improve clinical outcomes and administrative processes in healthcare delivery.

Beyond Therapeutics utilizes its ExCEED technology to accelerate the discovery and development of new medications targeting unmet therapeutic needs. This platform enhances the efficiency of drug development processes, reducing time-to-market for critical treatments.

Convalife Pharmaceuticals is developing novel therapeutics for tumor, viral, and age-related diseases, focusing on First-in-Class and Best-in-Class drug candidates, including second-generation PARP inhibitors and bispecific antibodies. The company addresses unmet clinical needs in oncology and infectious diseases by leveraging advanced drug discovery techniques and collaborations with leading research institutions.

QuantHealth utilizes a proprietary AI platform to conduct patient-centric drug simulations, enabling pharmaceutical and biotech companies to run extensive variations of clinical trials. This approach addresses the high failure rate of drugs in development, significantly increasing the probability of trial success and facilitating the discovery of new clinical opportunities.

BluMaiden uses advanced AI-guided discovery and computational chemistry to uncover human-derived natural product small molecules hidden within human biology. This approach translates "chemical dark matter" into novel therapeutic drug candidates that are inherently aligned with human biology for enhanced safety and specificity. The company integrates metagenomics, chemistry, and human physiology to accelerate the translation of overlooked molecular relationships into new medicines.

Signet Therapeutics develops targeted therapeutics that employ precision medicine techniques to identify and inhibit specific pathways in cancer cells. The company provides personalized treatment options for patients with various cancer types, addressing the limitations of traditional therapies.

Datomics Group provides a bioinformatics platform that utilizes machine learning and AI to analyze large volumes of scientific data, enhancing research efficiency and decision-making in life sciences. The platform integrates with laboratory instruments and complies with regulatory standards, enabling faster product development and optimized operations.

The startup develops targeted cancer therapeutics through advanced computational biology and drug discovery technologies, enabling precise identification of potential drug candidates. This approach addresses the challenge of inefficient cancer treatment development, facilitating faster and more effective therapies for clinicians and patients.

QuantHealth provides next-generation clinical AI for drug-patient simulations to guide clinical development decisions. The platform integrates biomedical, clinical, and epidemiological data into a unified framework for deep analysis. This enables optimization across clinical development, business development, and portfolio management use cases.

KaiFu Pharmaceuticals develops small molecule drugs using an affinity detection by mass spectroscopy (ADMS) platform to identify and optimize compounds for treating tumors and autoimmune diseases. Their lead candidates, KF-0210 and KBP-2205, target unmet medical needs in oncology and have advanced to clinical trial stages, providing potential new therapies for patients.

Zion Pharma is a drug discovery platform that utilizes computational biology and machine learning to identify potential drug candidates more efficiently. The platform addresses the high costs and lengthy timelines associated with traditional drug development processes by streamlining target identification and lead optimization.

BigHat Biosciences utilizes a machine learning-guided antibody design platform, Milliner, which integrates synthetic biology and high-speed wet lab processes to rapidly synthesize and characterize recombinant antibodies. The company focuses on developing safer and more effective antibody therapies for patients with challenging diseases, enhancing treatment options in the biopharmaceutical landscape.

KYAN Therapeutics utilizes its Optim.AI™ ex vivo analytic platform to perform functional precision medicine tests that evaluate drug response using patient-derived cancer cells. This approach addresses the limitations of standard therapies by providing personalized treatment regimens based on the unique sensitivities of each patient's cancer, thereby improving treatment efficacy.

ThinkCyte utilizes VisionSort, a technology that combines fluorescence flow cytometry with high-dimensional morphological profiling and AI for label-free cell sorting and unbiased single-cell profiling. This approach enables rapid identification and selection of therapeutically relevant cells, enhancing efficiency in cell therapy research and drug discovery.

CyberomiX utilizes digital technology to analyze DNA and gene expression at the cellular level, focusing on various diseases and conditions. The company provides a streamlined workflow for drug discovery and diagnostics by decoding genomic information from diverse clinical samples.

Remedi is a drug development company specializing in cell-penetrating peptides derived from human proteins, focusing on enhancing the delivery of cancer vaccines and therapies. Their IDDT platform utilizes a differentiated peptide library and AI-driven predictions to create dual-functional peptides for treating atopy and formulating cosmeceuticals.

Nine Biopharm develops peptidomimetic materials and utilizes its ARisT platform for computer simulation and remodeling to create new biomedical products, including drugs, medical devices, and cosmetics. The company addresses the need for innovative solutions in healthcare by repositioning existing drugs and commercializing diverse product pipelines to enhance human health and quality of life.

Gero develops therapeutics by applying physics-informed AI models trained on extensive longitudinal patient data to understand the root causes of aging. This platform distinguishes between irreversible aging and reversible disease processes to pinpoint targets that restore systemic resilience. The company focuses on designing interventions that delay age-related diseases and extend healthy human lifespan.